A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Germany- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Germany58 clinical trials in Bad Homburg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
GermanyThe busiest research cities in the country
What the registry says about research in the country
Groundbreaking research focusing on Alzheimer's Disease treatments and innovative therapies for Multiple Sclerosis. Studies are evaluating new compounds for disease modification and symptom management.
Additional trials explore treatments for migraine in both adults and pediatric populations.
Comprehensive studies targeting cardiovascular diseases and related conditions, including innovative approaches to treating atherosclerosis and managing blood pressure.
Focus on preventive treatments and long-term cardiovascular health maintenance.
Advanced clinical research in gynecologic oncology, including trials for ovarian and endometrial cancers, plus innovative approaches for colon cancer treatment.
Emphasis on combination therapies and personalized treatment approaches.
Tell us about your condition – we search every trial in Europe and connect you with the right site.